23andMe Stock

23andme.comHealthcare / Healthcare providers & servicesFounded: 2006Funding to Date: $876.61MM

23andMe is a consumer genetics and research company looking to help people access, understand, and benefit from the human genome.

Register To Buy and Sell Shares

For more details on financing and valuation for 23andMe, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access 23andMe’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like 23andMe.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Steve Schoch
Kenneth Hillan, M.B., Ch.B
Head of Therapeutics
Anne Wojcicki
CEO & Co-Founder
Fred Kohler
Vice President, People
Kathy Hibbs JD
Chief Legal & Regulatory Officer
Mike Polcari
Vice President & Chief Architect

Board Members

Patrick Chung
Roelof Botha
Sequoia Capital
Anne Wojcicki
Neal Mohan
Richard Scheller, Ph.D.

News Highlights

23andMe Study Associates Gene Locus With COVID-19-Related Loss of Smell, Taste
A multi-ancestry genome-wide association study found that genetics likely contributes to the loss of smell or taste in COVID-19 patients.
People in the News: New Appointments at Roswell Biotechnologies, 23andMe, Akoya Biosciences, More
23andMe to Acquire Telemedicine Platform Company Lemonaid Health for $400M in Cash, Stock
Lemonaid Health, based in San Francisco, offers a platform that provides online access to a variety of telemedicine and pharmacy services.
Updated on: May 26, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.